Nutritional and clinical predictors of intestinal maturation and feeding tolerance in the preterm infant
Nutritional and clinical predictors of intestinal maturation and feeding tolerance in the preterm infant
批准号:
10717469
负责人:
Robert Stephen Chapkin
金额:
$72.25万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-12 至 2028-05-31
关键词:
AbdomenAffectAntibioticsBenignBiological MarkersCaringCellsCharacteristicsClinicalDataDevelopmentDevelopmental BiologyDiagnosisDietDiseaseEarly DiagnosisEnteralEnteral FeedingEnteral NutritionExhibitsFunctional disorderGene ExpressionGenesGestational AgeGrowthHealthHospitalizationImmuneInfantInfant HealthInflammatoryInterventionIntestinal DiseasesIntestinal MucosaIntestinesIschemiaLifeMeasuresMetabolicMethodologyMucous MembraneNecrotizing EnterocolitisNeonatalNeonatal Intensive Care UnitsNeurocognitiveNormal RangeNutritionalNutritional SupportOutcomePathologicPathologyPhysiologicalPhysiologyPremature InfantProcessProspective cohortRecommendationResearchRiskRisk FactorsRouteSymptomsTestingTimeanalytical methodartificial neural networkbiomarker identificationclinical careclinical predictorsclinically relevantdietarydisorder riskearly detection biomarkersevidence baseextreme prematurityfecal microbiotafeedinggastrointestinalgastrointestinal signgastrointestinal symptomgut microbiomehigh riskhost microbiomeimprovedinsightintestinal injuryintestinal maturationischemic injurymachine learning algorithmmedical complicationmetabolomemetagenomemicrobialmicrobiomemicrobiome signatureneonatal periodnovelnovel markernutritionprecision medicineprecision nutritionprediction algorithmpreventresponsetooltranscriptome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract:
In 2020, 10% of U.S. infants were born preterm and ~2%, or 60,000 infants, were born very preterm (VPI; <32
weeks PMA). VPI infants are at high risk for of substantial medical complications, including necrotizing
enterocolitis (NEC). In VPI, advancing and maintaining nutritional support reduces disease risk and improves
neurodevelopmental outcomes; however, up to 25% of preterm infants demonstrate feeding intolerance, which
may be benign or may progress to NEC. However, precise measures and clinical tools that reliably differentiate
benign, intestinal immaturity from life-threatening symptoms are lacking. Therefore, the overall objective of this
application is to establish intestinal host and microbial biomarkers of intestinal function from an existing,
longitudinal, prospective cohort of 400 analyzable VPI and to relate those biomarkers to the spectrum of intestinal
function, from consistent enteral nutrition tolerance to intermittent intolerance to ischemic injury. For this purpose,
we will utilize our novel non-invasive (exfoliated mucosal cell) methodology to simultaneously assess host-
microbiome interactions in the VPI gut. Our central hypothesis is that the transgenomic cross-talk between
intestinal mucosal cells and the fecal metagenome and metabolome will provide mechanistic insight into the
spectrum of clinical presentations ranging from normal gut developmental biology to abnormal pathophysiology.
Three specific aims will test our central hypothesis. Aim 1 will annotate the host exfoliated mucosal cell
transcriptome and fecal bacterial metagenome and metabolome profiles to identify biomarkers for preterm infants
who have consistent tolerance to enteral feeding or who are diagnosed with feeding intolerance. Aim 2 will
annotate the host exfoliated mucosal cell transcriptome and fecal bacterial metagenome and metabolome
profiles to identify biomarkers for preterm infants who are diagnosed with feeding intolerance compared to those
who develop ischemia. Aim 3 will utilize machine learning algorithms to construct putative diet-health outcome
driven Artificial Neural Networks (ANNs). Completion of these aims will provide the necessary data to develop
predictive algorithms to enable identification of at-risk VPI who would benefit from precision medicine/nutrition
guided interventions targeting specific risk factors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting plasma membrane spatial dynamics to suppress aberrant Wnt signaling
-
批准号:10047029
-
项目类别:
-
资助金额:$57.92万
-
财政年份:2020
-
负责人:Robert Stephen Chapkin
-
依托单位:
Targeting plasma membrane spatial dynamics to suppress aberrant Wnt signaling
-
批准号:10401939
-
项目类别:
-
资助金额:$54.09万
-
财政年份:2020
-
负责人:Robert Stephen Chapkin
-
依托单位:
Diet and the colonic exfoliome: a novel, non-invasive approach to testing interventions in humans
-
批准号:10603601
-
项目类别:
-
资助金额:$19.05万
-
财政年份:2020
-
负责人:Robert Stephen Chapkin
-
依托单位:
Targeting plasma membrane spatial dynamics to suppress aberrant Wnt signaling
-
批准号:10630909
-
项目类别:
-
资助金额:$53.69万
-
财政年份:2020
-
负责人:Robert Stephen Chapkin
-
依托单位:
Targeting plasma membrane spatial dynamics to suppress aberrant Wnt signaling
-
批准号:10252842
-
项目类别:
-
资助金额:$55.28万
-
财政年份:2020
-
负责人:Robert Stephen Chapkin
-
依托单位:
Dietary Flavonoids-Microbiota-Ah Receptor Interactions in the Gut
-
批准号:9791345
-
项目类别:
-
资助金额:$35.43万
-
财政年份:2018
-
负责人:Robert Stephen Chapkin
-
依托单位:
Dietary Flavonoids-Microbiota-Ah Receptor Interactions in the Gut
-
批准号:10247052
-
项目类别:
-
资助金额:$33.94万
-
财政年份:2018
-
负责人:Robert Stephen Chapkin
-
依托单位:
Dietary and microbial predictors of childhood obesity risk
-
批准号:9892995
-
项目类别:
-
资助金额:$43.63万
-
财政年份:2017
-
负责人:Robert Stephen Chapkin
-
依托单位:
Role of Aryl Hydrocarbon Receptor in Microbiota-Colon Stem Cell Interactions
-
批准号:9102325
-
项目类别:
-
资助金额:$39.59万
-
财政年份:2016
-
负责人:Robert Stephen Chapkin
-
依托单位:
Molecular basis for dietary chemoprevention
-
批准号:10348744
-
项目类别:
-
资助金额:$80.62万
-
财政年份:2016
-
负责人:Robert Stephen Chapkin
-
依托单位:
Chemoprotective effects of natural products on colonic adult stem cells
-
批准号:9126694
-
项目类别:
-
资助金额:$9.68万
-
财政年份:2015
-
负责人:Robert Stephen Chapkin
-
依托单位:
Chemoprotective effects of natural products on colonic adult stem cells
-
批准号:8330239
-
项目类别:
-
资助金额:$29.87万
-
财政年份:2011
-
负责人:Robert Stephen Chapkin
-
依托单位:
Gut Microbiota and colonic gene expression: A ligran trial in humans
-
批准号:8330754
-
项目类别:
-
资助金额:$66.98万
-
财政年份:2011
-
负责人:Robert Stephen Chapkin
-
依托单位:
Chemoprotective effects of natural products on colonic adult stem cells
-
批准号:8704733
-
项目类别:
-
资助金额:$28.97万
-
财政年份:2011
-
负责人:Robert Stephen Chapkin
-
依托单位:
Chemoprotective effects of natural products on colonic adult stem cells
-
批准号:8902055
-
项目类别:
-
资助金额:$29.87万
-
财政年份:2011
-
负责人:Robert Stephen Chapkin
-
依托单位:
Chemoprotective effects of natural products on colonic adult stem cells
-
批准号:8513281
-
项目类别:
-
资助金额:$28.08万
-
财政年份:2011
-
负责人:Robert Stephen Chapkin
-
依托单位:
Gut Microbiota and colonic gene expression: A ligran trial in humans
-
批准号:8548301
-
项目类别:
-
资助金额:$61.71万
-
财政年份:2011
-
负责人:Robert Stephen Chapkin
-
依托单位:
Chemoprotective effects of natural products on colonic adult stem cells
-
批准号:8196591
-
项目类别:
-
资助金额:$29.75万
-
财政年份:2011
-
负责人:Robert Stephen Chapkin
-
依托单位:
Gut Microbiota and colonic gene expression: A ligran trial in humans
-
批准号:8726945
-
项目类别:
-
资助金额:$60.79万
-
财政年份:2011
-
负责人:Robert Stephen Chapkin
-
依托单位:
Gut Microbiota and colonic gene expression: A ligran trial in humans
-
批准号:8190626
-
项目类别:
-
资助金额:$72.0万
-
财政年份:2011
-
负责人:Robert Stephen Chapkin
-
依托单位:
海外基金